查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595485

龐貝氏症市場：依治療類型、分子類型、劑型、給藥途徑分類 - 全球預測 2025-2030

Pompe Disease Market by Therapy Type (Enzyme, Substrate), Molecule Type (Biologics, Small Molecules), Dosage Form, Route of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年龐貝氏症市場價值為15億美元，預計2024年將達15.9億美元，複合年成長率為5.61%，預計2030年將達到22.1億美元。

龐貝氏症是一種由體內細胞內肝醣累積引起的罕見遺傳疾病，它呈現出獨特的市場環境，其特徵是專門的治療需求和挑戰。該市場以酵素替代療法和潛在的基因療法為中心，可治療從嬰兒期到遲發性疾病的多種疾病類型。這種疾病的使人衰弱的性質強調了治療的必要性，它影響心臟和骨骼肌，凸顯了持續醫療干預的關鍵作用。主要應用領域包括遺傳研究、酵素開發和病患管理系統。最終用途主要是醫療設施、研究機構和專科診所，以進行這些治療和管理患者護理。

主要市場統計
基準年[2023] 15億美元
預測年份 [2024] 15.9億美元
預測年份 [2030] 22.1億美元
複合年成長率（%） 5.61%

市場成長在很大程度上受到生物技術進步和對罕見遺傳疾病認知不斷提高的影響，導致對更準確診斷和有效治療的需求增加。此外，政府透過孤兒藥指定和津貼來支持研究工作和藥物開發，為成長鋪平道路。個人化醫療的擴展以及CRISPR等新基因編輯技術的整合有望成為突破性的治療方法。然而，高昂的治療成本、有限的患者數量和嚴格的監管流程等挑戰構成了重大限制，影響了市場擴張。開發安全有效的治療方法的複雜性也阻礙了新興企業進入市場。

該領域的創新應側重於增強酶替代療法的傳遞系統、推進基因治療技術以及改進診斷工具以實現早期和準確的檢測。擴大合作研究舉措並探索與生物技術公司的策略夥伴關係可以提供寶貴的見解和資源並推動市場成長。儘管龐貝氏症市場的性質相對較小，但隨著技術能力的發展，預計將取得重大進展，使尖端研究能夠利用尖端研究實現治療創新，同時克服高成本和監管障礙。

市場動態：揭示快速發展的龐貝氏症市場的關鍵市場洞察

供需的動態交互作用正在改變龐貝氏症市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 龐貝氏症的蔓延
    • 長期治療的普及和診療的進步
    • 基因療法和酵素替代療法的發展加快
  • 市場限制因素
    • 龐貝氏症治療費用高昂
  • 市場機會
    • 加大研發投入
    • 政府致力於開發和製造創新產品
  • 市場問題
    • 缺乏治療意識

波特五力：駕馭龐貝氏症市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解龐貝氏症市場的外部影響

外部宏觀環境因素在塑造龐貝氏症市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解龐貝氏症市場的競爭格局

對龐貝氏症市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：龐貝氏症市場供應商績效評估

FPNV定位矩陣是評估龐貝氏症市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製龐貝氏症市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，龐貝氏症市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 龐貝氏病患病率增加
      • 長期治療的普及和診療的進步
      • 基因療法和酵素替代療法的進展
    • 抑制因素
      • 龐貝氏症的治療費用昂貴
    • 機會
      • 加大研發投入
      • 政府致力於開發和製造創新產品
    • 任務
      • 缺乏治療意識
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章龐貝氏症市場：依治療類型

  • 介紹
  • 酵素
  • 基板

第7章龐貝氏症市場：依分子類型

  • 介紹
  • 生技藥品
  • 小分子

第8章龐貝氏症市場：按劑型

  • 介紹
  • 液體
  • 固體的

第9章龐貝氏症市場：依給藥途徑

  • 介紹
  • 口服
  • 由監護人

第10章美洲龐貝氏症市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太龐貝氏症市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲龐貝病市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Astellas Pharma Europe Ltd
  • B Braun Melsungen AG
  • Becton, Dickinson & Company
  • CENTOGENE NV
  • Flowserve Corporation
  • Genethon
  • GlaxoSmithKline PLC
  • Koninklijke Philips NV
  • Merck KGaA
  • Novartis AG
  • Oxyrane UK Ltd.
  • Pfizer Inc.
  • Pharming Group NV
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-035AB9C0DAD1

The Pompe Disease Market was valued at USD 1.50 billion in 2023, expected to reach USD 1.59 billion in 2024, and is projected to grow at a CAGR of 5.61%, to USD 2.21 billion by 2030.

Pompe Disease, a rare inherited disorder resulting from the buildup of glycogen in the body's cells, presents a unique market landscape characterized by specialized therapeutic needs and challenges. The scope of the market centers on enzyme replacement therapies and potential gene therapies to address varying forms of the disease, ranging from infantile-onset to late-onset Pompe Disease. The necessity for treatment is underscored by the disease's debilitating nature, which impacts cardiac and skeletal muscles, emphasizing the vital role of ongoing medical intervention. Key application areas include genetic research, enzyme development, and patient management systems. End-use primarily involves healthcare facilities, research institutes, and specialty clinics equipped to administer these treatments and manage patient care.

KEY MARKET STATISTICS
Base Year [2023] USD 1.50 billion
Estimated Year [2024] USD 1.59 billion
Forecast Year [2030] USD 2.21 billion
CAGR (%) 5.61%

Market growth is significantly influenced by advances in biotechnology and increasing awareness of rare genetic disorders, leading to more accurate diagnoses and increased demand for effective treatments. Furthermore, governmental support through orphan drug designations and grants propels research endeavors and drug development, creating avenues for growth. Potential opportunities abound in the expansion of personalized medicine and the integration of novel gene-editing technologies like CRISPR, which hold promise for groundbreaking interventions. However, challenges such as high treatment costs, limited patient population, and stringent regulatory processes pose considerable limitations and impact market expansion. The complexity of developing safe and effective therapies also deters market entry for new firms.

Innovation in this field should focus on enhancing delivery systems for enzyme replacement therapies, advancing genetic therapy techniques, and improving diagnostic tools for early and accurate detection. Expanding collaborative research initiatives and exploring strategic partnerships with biotech firms can provide valuable insights and resources, fostering market growth. The nature of the Pompe Disease market is relatively niche yet poised for substantial advancement as technological capabilities evolve, presenting significant potential for firms that can navigate the high barriers of cost and regulation while leveraging cutting-edge research for therapeutic innovation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pompe Disease Market

The Pompe Disease Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of pompe disease
    • Uptake of long term therapies and advancement in the diagnosis and treatment
    • Increasing developments in the gene therapy and enzyme replacement therapies
  • Market Restraints
    • High treatment costs of pompe diseases
  • Market Opportunities
    • Increasing investment in the research and development
    • Government initiatives for the development and manufacture of innovative products
  • Market Challenges
    • Lack of awareness about the treatment

Porter's Five Forces: A Strategic Tool for Navigating the Pompe Disease Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pompe Disease Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pompe Disease Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pompe Disease Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pompe Disease Market

A detailed market share analysis in the Pompe Disease Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pompe Disease Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pompe Disease Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pompe Disease Market

A strategic analysis of the Pompe Disease Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pompe Disease Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Europe Ltd, B Braun Melsungen AG, Becton, Dickinson & Company, CENTOGENE N.V., Flowserve Corporation, Genethon, GlaxoSmithKline PLC, Koninklijke Philips NV, Merck KGaA, Novartis AG, Oxyrane UK Ltd., Pfizer Inc., Pharming Group NV, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Pompe Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapy Type, market is studied across Enzyme and Substrate.
  • Based on Molecule Type, market is studied across Biologics and Small Molecules.
  • Based on Dosage Form, market is studied across Liquid and Solid.
  • Based on Route of Administration, market is studied across Oral and Parental.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of pompe disease
      • 5.1.1.2. Uptake of long term therapies and advancement in the diagnosis and treatment
      • 5.1.1.3. Increasing developments in the gene therapy and enzyme replacement therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High treatment costs of pompe diseases
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investment in the research and development
      • 5.1.3.2. Government initiatives for the development and manufacture of innovative products
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness about the treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pompe Disease Market, by Therapy Type

  • 6.1. Introduction
  • 6.2. Enzyme
  • 6.3. Substrate

7. Pompe Disease Market, by Molecule Type

  • 7.1. Introduction
  • 7.2. Biologics
  • 7.3. Small Molecules

8. Pompe Disease Market, by Dosage Form

  • 8.1. Introduction
  • 8.2. Liquid
  • 8.3. Solid

9. Pompe Disease Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Oral
  • 9.3. Parental

10. Americas Pompe Disease Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pompe Disease Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pompe Disease Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Astellas Pharma Europe Ltd
  • 2. B Braun Melsungen AG
  • 3. Becton, Dickinson & Company
  • 4. CENTOGENE N.V.
  • 5. Flowserve Corporation
  • 6. Genethon
  • 7. GlaxoSmithKline PLC
  • 8. Koninklijke Philips NV
  • 9. Merck KGaA
  • 10. Novartis AG
  • 11. Oxyrane UK Ltd.
  • 12. Pfizer Inc.
  • 13. Pharming Group NV
  • 14. Sanofi S.A.
  • 15. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. POMPE DISEASE MARKET RESEARCH PROCESS
  • FIGURE 2. POMPE DISEASE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL POMPE DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL POMPE DISEASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL POMPE DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS POMPE DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS POMPE DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES POMPE DISEASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES POMPE DISEASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. POMPE DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. POMPE DISEASE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. POMPE DISEASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL POMPE DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL POMPE DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. POMPE DISEASE MARKET DYNAMICS
  • TABLE 7. GLOBAL POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL POMPE DISEASE MARKET SIZE, BY ENZYME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL POMPE DISEASE MARKET SIZE, BY SUBSTRATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL POMPE DISEASE MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL POMPE DISEASE MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL POMPE DISEASE MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL POMPE DISEASE MARKET SIZE, BY SOLID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL POMPE DISEASE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL POMPE DISEASE MARKET SIZE, BY PARENTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES POMPE DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. JAPAN POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. MALAYSIA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. TAIWAN POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. THAILAND POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. VIETNAM POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 103. DENMARK POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. EGYPT POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. FINLAND POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. FRANCE POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. GERMANY POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. ISRAEL POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. ITALY POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. NETHERLANDS POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. NIGERIA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NORWAY POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. POLAND POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. QATAR POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. RUSSIA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. SAUDI ARABIA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH AFRICA POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SPAIN POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SWEDEN POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWITZERLAND POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. TURKEY POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED ARAB EMIRATES POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. POMPE DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 188. POMPE DISEASE MARKET, FPNV POSITIONING MATRIX, 2023